



ASX Announcement

5 September 2023

BCAL APPOINTS SHANE RYAN AS CHIEF OPERATING OFFICER

BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) an Australian-based biotechnology company developing a blood test for breast cancer is pleased to announce the appointment of Mr Shane Ryan as Chief Operating Officer (COO), effective 21 September 2023.

Shane will be responsible for the overall operation and administration of BCAL's clinical affairs, physician relationships, clinical product marketing, promotion, strategy, and business development.

BCAL co-founder and executive chair Jayne Shaw, said: "We are delighted to welcome Shane to the BCAL Executive team. He brings a depth of knowledge and experience to our organisation which will be invaluable as we move our BREASTEST™ to the market next year. He is widely known and respected as a trusted partner and collaborator in the Global breast cancer community."

"Shane will be responsible for fostering connections with global oncology key opinion leaders and breast surgeons. He will be integral in developing the strategy for acquiring samples from prospective cancer patients, especially near-term breast cancer cases, advancing the BCAL Biobank ready for commercialisation in 2024. Shane will also ensure global compliance with legal, ethical, and IRB standards for comprehensive patient sample collection and testing."

Before joining BCAL, Shane was most recently the Global Senior Vice President Strategy & Innovation – Patient Access for GenesisCare. Shane has more than 20 years' experience in the global oncology market and in particular breast cancer. He has an extensive Oncology network and deep understanding of what is critically important to both cancer patients, their treating Oncologist, and the extended multidisciplinary team. His experience covers patient care, research, innovative service delivery models, and commercial aspects of cancer patient management.

Shane was also responsible for the introduction of the highly successful precision medicine test for Ductal Carcinoma In-situ (DCISionRT), providing access for Australian women for the first time in addition to this 1500 Nation-wide clinical registry. Shane has also originated other clinical trials and evaluations of predictive and management tools for the management of high-risk breast cancer patients in Australia.

Prior to joining GenesisCare, Mr Ryan spent 10 years with globally recognised Peter MacCallum Cancer Centre where he held Executive positions in Clinical Operations, Services Development and Surgery.

Shane Ryan commented: "I am excited to join BCAL at this pivotal time as the BREASTEST™ moves down the pathway to commercialisation next year. This test will be a valuable addition to the tools available for the detection and management of breast cancer. BREASTEST™ will be a game changer for women in the fight against the disease".

This announcement has been approved for release to the ASX by the Board.

ENDS

Jayne Shaw

Executive Chair

Jshaw@bcaldiagnostics.com

John Hurrell

Chief Executive Officer

jhurrell@bcaldiagnostics.com

ABOUT BCAL DIAGNOSTICS

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating 90% specificity and 85% accuracy. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com/>